SEC Form 4 · accession 0001193125-26-267764
Jade Biosciences, Inc. · JBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher W. Cain
Director
Period of report
Jun 9, 2026
Accepted (ET)
Jun 11, 2026 · 4:47 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001798749
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $15.22 | Jun 9, 2026 | A | 34,843 | A | — | Jun 8, 2036 | Common Stock | 34,843 | 34,843 | D |
Explanation of responses
- F1This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.
- F2Under the Reporting Person's arrangement with Fairmount Funds Management LLC ("Fairmount"), the Reporting Person holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.